bioRxivBiochemistryPreprint
In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction
A. D'Alessandro, M. Nouraie, Y. Zhang, F. Cendali, F. Gamboni, J. A. Reisz, X. ZhangiD, K. W. Bartsch, M. D. Galbraith, V. R. Gordeuk, M. T. Gladwin
Abstract
Despite a wealth of exploratory plasma metabolomics studies in sickle cell disease (SCD), no study to date has evaluate a large and well phenotyped cohort to compare the primary erythrocyte metabolome of hemoglobin SS, SC and transfused AA red blood cells (RBCs) in vivo. The current study evaluates the RBC metabolome of 587 subjects with sickle cell sickle cell disease (SCD) from the WALK-PHaSST clinical cohort. The set includes hemoglobin SS, hemoglobin SC SCD patients, with variable levels of HbA related to RBC transfusion events, and HbF related to hydroxyurea therapy. Here we explore the modulating effects of genotype, age, sex, severity of hemolysis, and hydroxyurea and transfusion therapy on sickle RBC metabolism. Data - collated in an online portal - show that the Hb SS genotype is associated with significant alterations of RBC acylcarnitines, pyruvate, sphingosine 1-phosphate, creatinine, kynurenine and urate metabolism. Surprisingly, the RBC metabolism of SC RBCs is dramatically different from SS, with all glycolytic intermediates significantly elevated in SS RBCs, with the exception of pyruvate. This result suggests a metabolic blockade at the ATP-generating phosphoenolpyruvate to pyruvate step of glycolysis, which is catalyzed by redox-sensitive pyruvate kinase. Increasing in vivo concentrations of HbA improved glycolytic flux and normalized the HbS erythrocyte metabolome. An unexpectedly limited metabolic effect of hydroxyurea and HbF was observed, possibly related to the modest induction of HbF in this cohort. The metabolic signature of HbS RBCs correlated with the degree of steady state hemolytic anemia, cardiovascular and renal dysfunction and mortality. Key pointsO_LIIn vivo dysregulation of RBC metabolism by HbS is evaluated by metabolic profiling of 587 patients with variable HbA, HbC and HbF levels; C_LIO_LIRBC acyl-carnitines, urate, pyruvate metabolism, S1P, kynurenine relate to hemolysis and cardiorenal dysfunction, respond to transfusion; C_LI
- organism: human
- assay: metabolomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: metabolism & bioenergetics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment
A. D'Alessandro, M. Nouraie, … M. T. Gladwin·HaematologicaPeer-reviewed·Jul 13, 2023
- Hemoglobin C is prone to oxidative denaturation, resulting in red blood cell membrane damage in HbSC disease
Tahereh Setayesh, Anifat Tijani, … Punam Malik·bioRxiv·Jun 10, 2026
- Structural insights into the inhibition of sickle hemoglobin polymerization by asymmetric hemoglobin tetramer HbFS (α2γβS)
Aastha Baliyan, Neha Yadav, … Amit Kumar Mandal·bioRxiv·Jun 7, 2026
- Biophysical Basis of Hb-S Polymerization in Red Blood Cell Sickling
W. Li·bioRxiv·Jun 21, 2019
- Transcriptomic profiling of an ex vivo model of erythropoiesis uncovers potential genes and pathways involved into the pathogenesis of sickle cell disease
Matthis Tinguely, Lennart Opitz, … Francesca Daniela Franzoso·bioRxiv·Sep 26, 2023
- Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease mice
Nicole H. Lopez, Yaqin Li, … Betty S. Pace·PLoS ONEPeer-reviewed·May 31, 2022